ENTITY: Sanofi SA

A Macro Intelligence Memo | June 2030 | CEO Edition

FROM: The 2030 Report DATE: June 2030 RE: Pharmaceutical Portfolio Transformation Through Vaccine Leadership and AI Drug Discovery Investment - Strategic Repositioning During Market Disruption

SUMMARY: THE BEAR CASE vs. THE BULL CASE

BEAR CASE (Measured Portfolio Transformation - Actual Path)

Sanofi expands vaccine portfolio (RSV revenue grows to €4.8B), maintains specialty care business (€22B revenue), invests measured €500M-€800M annually in AI drug discovery. Revenue CAGR 2025-2030: 4-6% (€44B to €56B). Operating margin reaches 24-26%. Dividend maintained €1.80-2.20 per share. Stock appreciation targets 9-11% annually.

Financial Impact (Bear Case 2035): - Revenue: €68-72B - Operating Margin: 26-28% - Vaccine % Revenue: 8-10% - Stock CAGR 2030-2035: 9-11%

BULL CASE (Aggressive AI Drug Discovery + Vaccine Dominance - 2025)

Had Sanofi committed €2-3B annually to AI drug discovery and acquired 2-3 biotech platforms in 2025-2027, while aggressively pursuing vaccine expansion (COVID boosters, pan-respiratory vaccines), the company would have achieved 6-8% revenue CAGR and 28-30% operating margins by 2030. Pipeline launches accelerate to 3-4 annually by 2033. Dividend growth reaches €2.20-2.60 per share. Stock CAGR reaches 12-14%.

Financial Impact (Bull Case 2035): - Revenue: €75-80B - Operating Margin: 28-30% - Vaccine % Revenue: 12-15% - Stock CAGR 2030-2035: 12-14%

EXECUTIVE SUMMARY

Sanofi's CEO-level strategic positioning during 2024-2030 centered on a decisive portfolio transformation: simultaneously defending incumbent vaccine business while committing substantial capital to emerging AI-driven drug discovery capabilities. This dual strategy—maintaining near-term revenue stability through vaccine expansion while building long-term competitive advantage through AI research—represented a bet that the pharmaceutical industry's future belonged to organizations capable of operating across both traditional development and AI-accelerated discovery paradigms.

Key metrics: - Revenue (FY2024): €44.2 billion - Revenue (FY2030): €55.8 billion (+26% growth, CAGR +4.2%) - Operating margin (FY2030): 24.5% (vs. 21.3% FY2024) - RSV vaccine revenue (FY2030): €4.8 billion (+50%+ annually) - Specialty care revenue: €22.3 billion (40% of total), +4-6% annual growth - Vaccines revenue: €11.2 billion (20% of total), +6-8% annual growth - AI R&D investment (2030-2032): €2-3 billion committed - Computational scientist hiring: 800+ positions targeted through 2032 - AI drug discovery programs: 12-15 Phase 1-2 programs by 2032 (vs. 4 in 2024) - Generics portfolio decline: Accepted 15-18% annual decline in low-margin generics business - Total shareholder return (2024-2030): +87% (including dividends)

Sanofi's strategic positioning reflected a fundamental insight: the pharmaceutical industry was bifurcating into (1) AI-accelerated discovery organizations capable of generating new drug candidates at unprecedented velocity, and (2) traditional pharmaceutical companies facing pipeline sustainability challenges as patent cliffs accelerated. CEO leadership required choosing which future the company would inhabit.

SECTION 1: MARKET CONTEXT AND STRATEGIC IMPERATIVES

The Pharmaceutical Industry Transformation (2024-2030)

The global pharmaceutical industry experienced profound transformation between 2024-2030, driven by three convergent forces:

1. AI-Accelerated Drug Discovery: AI systems for compound screening, target identification, and clinical trial design began demonstrably reducing drug discovery timelines. Where traditional discovery took 10-12 years from compound identification to Phase 1 trial, AI-assisted discovery achieved comparable results in 4-6 years. Companies like Exscientia, Recursion Pharma, and Schrödinger achieved measurable improvements in hit-to-lead timelines.

2. Patent Cliff Acceleration: Blockbuster drugs (revenue >$1 billion annually) began losing patent protection: Humira (AbbVie) lost exclusivity in 2023, followed by Dupilumab, Opdivo, and others. This meant revenue declines of $500 million-$1.2 billion annually for major pharmaceutical companies that failed to replace blockbusters with new drug launches.

3. Specialty Care and Biologics Growth: While traditional small-molecule drugs faced genericization, specialty biologics (cancer treatments, rare disease therapies, immunotherapies) grew 12-15% annually. Companies with strong specialty care portfolios outperformed peers.

These dynamics created existential pressure on traditional pharmaceutical R&D. Companies pursuing traditional drug discovery faced: (a) lower probability of success (7-8% of drug candidates reach approval vs. 2-3% historically), (b) extended timelines (growing regulatory scrutiny), and (c) declining patent protection value (shorter de facto exclusivity periods). The return on R&D investment was declining, creating pressure to reduce research spending or shift toward more productive modalities.

Strategic implications for Sanofi: - Blocking: Sanofi generated €22.3 billion from specialty care (oncology, immunology, rare disease) growing 4-6% annually, providing defensive revenue base - Vulnerability: Pipeline sustainability required discovering new drugs faster and more cost-effectively than traditional methods enabled - Opportunity: AI drug discovery represented genuine capability advantage for organizations committing resources, but required sustained multi-year investment before ROI materialized

Sanofi's Historical Position and Vulnerabilities (2024)

Entering 2024, Sanofi was a well-established but incumbent pharmaceutical company:

Strengths: - Global presence: 19.2 billion revenue in developed markets, 24.8 billion in emerging markets - Specialty care franchise: Strong positions in oncology (Yervoy, Jevtana), immunology (Dupilumab), rare disease - Vaccine business: Established capabilities in flu, pneumococcal, meningococcal vaccines - Financial resources: €12.4 billion annual operating cash flow enabling substantial R&D investment

Vulnerabilities: - Patent cliffs: Dupilumab (€3.9B revenue, 2024) faced declining exclusivity; Hyrimoz (biosimilar of Humira) facing competition; Opdivo (oncology) experiencing generic/biosimilar pressure - AI drug discovery gap: Sanofi's drug discovery remained predominantly traditional; no major AI-driven platforms operational by 2024 - Generics dependency: €8.2 billion (18.6%) of revenue from low-margin generics business facing persistent genericization pressure - Vaccine portfolio concentration: RSV vaccine (approved 2024) would drive growth, but portfolio was concentrated on handful of programs

The CEO strategic question: How does Sanofi navigate tension between (a) defending incumbent franchise threatened by patent cliffs and (b) investing heavily in AI drug discovery when ROI timeline extended 5-7 years and success uncertain?

SECTION 2: THE THREE-PILLAR STRATEGY - VACCINES, SPECIALTY CARE, AND AI TRANSFORMATION

Pillar 1: Vaccine Portfolio Expansion and RSV Blockbuster Execution

The RSV (Respiratory Syncytial Virus) vaccine represented a genuine pharmaceutical innovation: first-ever approved RSV vaccine, addressing unmet medical need in older adults and potentially pregnant women (for neonatal protection). By 2024, clinical efficacy data demonstrated 94% effectiveness in preventing RSV-associated illness in elderly populations—a clear public health advance.

Market opportunity: RSV affects 14 million elderly patients annually globally, with no prior effective preventive. Potential addressable market: €8-12 billion annually at peak penetration. First-to-market advantage was substantial.

Sanofi's RSV vaccine execution (2024-2030):

By June 2030, RSV vaccine had achieved €4.8 billion in annual revenue, exceeding initial forecasts. Key factors: - Clinical efficacy: 94% effectiveness generated rapid adoption; physician confidence high - Pricing: $400-500 per dose, reflecting genuine innovation premium vs. commodity vaccines - Uptake velocity: Penetration of eligible elderly population reached 31% by 2030 (vs. 15% forecasted), driven by strong safety profile and media attention to RSV risk - Expansion indications: Sanofi successfully pursued expansion into pregnant women (neonatal protection indication), adding upside to base market estimate

RSV vaccine success created several strategic implications: - Financial impact: Gross margin on RSV ~78% (vs. traditional vaccines 48-52%), contributing disproportionately to overall profitability - Organizational validation: RSV success proved Sanofi could execute on modern vaccine development, supporting internal narrative that vaccine business remained core strategic priority - Talent attraction: RSV success attracted world-class vaccinology talent, strengthening bench for future vaccine programs

CEO strategic decision on vaccine expansion:

Riding RSV success, Sanofi committed €2-3 billion (2025-2032) to develop next-generation vaccines: - Dengue vaccine: Addressable market €3-5 billion globally; Sanofi was second-mover (after Takeda/Dengvaxia) but with improved safety profile - Mpox vaccine: Expanding beyond current smallpox-derived vaccines; Sanofi developed novel platform - Lyme disease vaccine: Addressing vaccine gap (previous Lymerix vaccine withdrawn in 1990s due to safety concerns/litigation); new platform addressed historical safety perceptions

Investment rationale: - Vaccines offered high margins (75%+ gross margin vs. 35-45% for specialty care) - Patent protection through composition-of-matter and method patents enabled durable pricing power - Market growth: Vaccine markets growing 12-15% annually, faster than traditional pharmaceuticals - Pipeline sustainability: Vaccine programs required 6-8 year development vs. 10-14 years for traditional drugs, enabling faster revenue replacement

Target: Vaccines growing from 20% of revenue (€11.2B, 2030) to 25% by 2035 (projected €14-16B based on compound growth)

This strategy represented partial retreat from traditional small-molecule pharmaceuticals toward higher-margin, faster-development vaccine modality.

Pillar 2: Specialty Care Consolidation and Lifecycle Management

Sanofi's specialty care franchise (€22.3 billion, 2030) represented near-term revenue stability and margin strength. CEO strategy emphasized lifecycle management and indication expansion:

Dupilumab (immunology/dermatology): Despite facing exclusivity erosion beginning 2026, Sanofi pursued aggressive indication expansion: - Original indications (atopic dermatitis, asthma): €2.4B revenue by 2024 - Expansion indications (COPD, eosinophilic granulomatosis with polyangiitis): Added €800M+ revenue by 2030 - Lifecycle management: Patent term extension, combination therapy development, pediatric indications extending exclusivity

Yervoy/Opdivo (oncology): Facing generic/biosimilar competition, Sanofi focused on combination regimens: - Yervoy + combination immunotherapy regimens: Extending clinical utility and justifying premium pricing - Expanded indication portfolio: Melanoma, NSCLC, renal cell carcinoma, hepatocellular carcinoma

Strategy: Rather than develop entirely new molecules, leverage existing assets through indication expansion, combination therapy, lifecycle management. This approach: - Accelerated time-to-revenue vs. developing new drugs (2-4 years vs. 8-12 years) - Leveraged existing manufacturing, distribution, sales infrastructure - Generated incremental margins on expanded indications - Sustained patient access and demonstrated commitment to therapeutic areas

Margin impact: Specialty care maintained 45-48% gross margins despite patent pressure, supported by volume growth and indication expansion

Pillar 3: AI Drug Discovery Investment and Long-Term Capability Building

The most strategically consequential CEO decision was committing €2-3 billion to AI drug discovery transformation during 2030-2032 period. This represented bet that traditional pharmaceutical R&D was becoming obsolete, and organizations failing to transition to AI-accelerated discovery would face pipeline sustainability challenges by 2033-2035.

The AI drug discovery investment thesis:

By 2028-2030, evidence was accumulating that AI-accelerated drug discovery meaningfully improved productivity: - Exscientia's AI-designed IBD drug reached Phase 2 in 48 months vs. 7 years average - DeepMind's AlphaDiskover improved protein structure prediction, accelerating target identification - Recursion Pharma demonstrated 40-50% improvement in lead optimization timelines

However, translating these successes into organizational capability required:

1. Talent acquisition (800+ computational scientists by 2032): Sanofi launched aggressive recruiting targeting: - PhD-level computational chemists and biologists from tech companies and academic institutions - Machine learning engineers experienced in drug discovery (recruited from biotech, AI startups) - Drug discovery informatics specialists

Compensation: €150,000-€280,000 for senior computational scientists (top of European pharmaceutical range), drawing talent from competitive markets. This represented €320-400 million annual cost by 2032 at full hiring levels.

2. Platform infrastructure investment (€800 million 2030-2032): - Computational infrastructure: GPU clusters, cloud partnerships (AWS, Google Cloud for AI model training) - Software platforms: Licensing/acquiring AI drug discovery platforms (partnerships with Schrödinger, Recursion, others) - Data infrastructure: Building proprietary datasets of Sanofi's historical chemistry, biology, clinical data to train internal models

3. Partnership and licensing strategy: Rather than build all AI capability internally, Sanofi pursued strategic partnerships: - Google DeepMind: Joint research on protein structure prediction and drug target identification - Recursion Pharma: Licensing AI platform for hit-to-lead optimization - Schrödinger: Partnership on computational chemistry and ADME prediction - Academic partnerships: MIT, Stanford, Cambridge on computational biology

Partnership costs: €120-150 million annually through 2032

4. Organizational structure: By 2030, Sanofi had established separate "AI Drug Discovery" division with 220 computational scientists (ramping to 800+ by 2032). Structure: - Discovery informatics: Target identification, AI-driven validation - Computational chemistry: Lead optimization, property prediction - AI-assisted design: Integration of ML models into chemists' workflows - Platform engineering: Building internal ML models and tools

Leadership: Recruited world-class computational biology executive from Genentech/Roche as division head, signaling organizational commitment.

Expected outcomes by 2032: - 12-15 Phase 1-2 programs annually from AI-assisted discovery (vs. 4-5 from traditional discovery) - 35-40% improvement in discovery-to-Phase 1 timelines - Estimated NPV of AI-derived pipeline: €3.5-4.2 billion (justifying €2-3B investment if success rates improve as projected)

SECTION 3: PORTFOLIO RATIONALIZATION - THE DIFFICULT DECISION ON GENERICS

The Generics Problem

Sanofi's generics business—€8.2 billion in 2024, representing 18.6% of revenue—was hemorrhaging value:

Margin pressure: Generic drug prices declined 8-12% annually as competition intensified and generic penetration expanded. Gross margins compressed from 35% (2020) to 22% (2024).

Competitive dynamics: Generics market was consolidating around a few low-cost producers (Teva, Mylan/Viatris, Sandoz). Sanofi's cost structure was 30-40% above peers due to legacy manufacturing footprint and distribution model.

Strategic fit: Generics offered no intellectual property moat, required massive manufacturing investment to achieve cost competitiveness, and generated declining margins.

CEO strategic decision: Accept declining generics business rather than invest in competitiveness.

This was counterintuitive but financially rational:

Option A (Attempted competitiveness): Invest €1.5-2 billion to consolidate manufacturing, improve cost structure, achieve competitive positioning. This would require 3-4 years to achieve payback, tying up capital and management attention during critical AI drug discovery ramp.

Option B (Rationalization): Accept generics business declining 15-18% annually (natural market forces), gradually divest underperforming assets, reallocate capital to vaccines and AI drug discovery.

Option B was selected. By 2030, Sanofi had: - Divested generics operations in India and Turkey (lower-cost markets where Sanofi couldn't compete) - Consolidated European generics into single manufacturing footprint (Czech Republic facility) - Reduced generics headcount by 2,100 employees - Accepted generics revenue declining to €6.8B (2030) with clear trajectory toward €4-5B by 2033

Rationale: Capital and management attention were scarce resources. Investing either toward defending generics business or toward AI drug discovery was binary choice. CEO determined AI discovery pathway created more value long-term.

Employee and shareholder impact: - Workforce reduction (2,100 employees) created near-term costs (€420M severance/restructuring) - Short-term revenue decline concern mitigated by vaccine and AI growth offsetting generics decline - Strategic clarity about business portfolio supported stock performance despite revenue headwind

SECTION 4: CAPITAL ALLOCATION FRAMEWORK AND FINANCIAL ENGINEERING

Operating Margin Expansion Despite Revenue Deceleration

Sanofi achieved remarkable profitability improvement: operating margin expanded from 21.3% (2024) to 24.5% (2030) despite growth decelerating from historical 6-8% annually to 4.2% CAGR over this period.

This was accomplished through:

1. Portfolio mix shift: Vaccines and specialty care (combined 60% of revenue) carried 48-50% gross margins vs. generics (25%). As high-margin products grew as percentage of portfolio, operating margin expanded.

2. Scale leverage in operations: Despite headcount reduction (from 108,000 to 101,000 employees), Sanofi improved distribution, manufacturing scale, and process efficiency. SG&A expenses (selling, general, administrative) declined from 28% of revenue to 24%.

3. R&D productivity improvements: Traditional R&D spending remained stable (~€5.2B annually), but AI platform leverage meant more drug candidates could be advanced per R&D dollar. This improved "productivity per R&D spend."

4. Divestiture proceeds: Generics business sale proceeds (€1.8B) and divested non-core assets generated one-time gains supporting reported earnings

Net result: Operating profit increased from €9.4B (2024) to €13.7B (2030) on only 26% revenue growth, demonstrating exceptional operational leverage.

Capital Allocation Priorities

CEO-directed capital allocation (€13.7B annual operating profit) was distributed:

1. R&D investment (€5.2B annually): - Traditional pharmaceutical discovery: €2.8B (5% of revenue) - Vaccines R&D: €1.1B (10% of vaccine revenue) - AI drug discovery platform: €1.3B (growing toward €2B+ by 2032)

2. Dividend and shareholder returns (€4.8B annually): - Dividend yield: 2.6% of stock price - Share buybacks: €1.2B annually - Represented return of ~35% of free cash flow to shareholders

3. Strategic M&A (€1.2B annually deployment): - Acquisitions of AI drug discovery companies (Schrödinger minority stake, partnership with Recursion) - Biotech acquisitions filling pipeline gaps (3-4 acquisitions annually, €200-600M each)

4. Debt reduction and balance sheet optimization (€2.5B annually): - Net debt declining from €5.2B (2024) to €2.8B (2030) - Investment-grade credit rating maintained - Preserved financial flexibility for potential major M&A or partnership commitments

SECTION 5: COMPETITIVE POSITIONING AND THE ROCHE CHALLENGE

Roche's AI Advantage and Competitive Pressure

The competitive threat providing urgency to Sanofi's AI investment was Roche's earlier and more aggressive commitment to AI drug discovery. Roche had:

• Earlier AI investment (partnerships with Deep Genomics, preclinical 2022-2023 vs. Sanofi 2025-2026)
• Larger AI hiring (1,200+ computational scientists vs. Sanofi's 800+)
• Integrated AI into traditional discovery more systematically
• Proprietary AI platforms (Roche had deeper investment in internal model development vs. Sanofi's partnership approach)

By 2030, Roche was demonstrating tangible AI advantage: 6-8 Phase 1-2 programs annually from AI-assisted discovery vs. Sanofi's 3-4 (ramping toward 12-15 by 2032 based on plans). This pipeline velocity advantage, if sustained, would result in: - More drug candidates reaching market - Faster pipeline replacement as blockbusters faced patent cliffs - Premium valuations reflecting AI productivity advantage

CEO strategic response: Rather than accept Roche leadership position, Sanofi committed to catching up rapidly through aggressive hiring (800+ computational scientists), platform partnerships, and portfolio focus on areas where AI advantage would be most meaningful (certain oncology and immunology targets).

The race was genuine: organizations that achieved world-leading AI drug discovery capability by 2033-2035 would maintain competitive advantage as traditional discovery became increasingly obsolete. Sanofi's 2025-2032 AI investment commitment was response to this competitive pressure.

SECTION 6: FINANCIAL PERFORMANCE AND SHAREHOLDER VALUE

Total Shareholder Return

Despite business model transformation challenges, Sanofi generated strong shareholder returns:

Stock price (June 2024): €96.40 Stock price (June 2030): €180.25 Capital appreciation: +87%

Dividends received (2024-2030): €18.30 per share (approximately 8.4% cumulative yield)

Total shareholder return: +95.4%

This outperformed broader pharmaceutical indices (Nasdaq Pharma: +47%, S&P 500: +62% over same period) and validated CEO strategy despite business model disruption.

Valuation metrics: - Price-to-earnings (June 2030): 18.2x - EV/EBITDA: 12.4x - Dividend yield: 2.6% - 5-year EPS growth forecast: 8-10% annually (driven by vaccine portfolio and AI pipeline)

Key Performance Indicators (CEO Dashboard)

CEO success measured against internal KPIs:

Most KPIs tracking toward or exceeding targets by June 2030.

CONCLUSION: PORTFOLIO TRANSFORMATION AS EXISTENTIAL IMPERATIVE

Sanofi's CEO-level strategic decision-making during 2024-2030 reflected profound recognition that traditional pharmaceutical business model was facing existential transformation. The response—simultaneously defending near-term revenue through vaccine expansion, maintaining profitability in specialty care, and committing substantial capital to AI drug discovery—represented coherent strategy for navigating this transition.

By June 2030, the strategy was vindicated by: - Strong financial performance (operating margin expansion, shareholder returns) - Portfolio mix improvement (higher-margin vaccines and specialty care driving growth) - Competitive positioning (narrowing gap with Roche on AI drug discovery, establishing credible voice in conversation about pharmaceutical future)

The critical question for 2030s: Will Sanofi's AI drug discovery investment achieve productivity improvements promised (improving hit-to-lead timelines by 35-40%, improving success rates from 8% to 12-14%)? If yes, the company will have successfully navigated industry transformation and positioned for 2030-2040 period of sustainable competitive advantage.

If AI drug discovery fails to deliver promised improvements, Sanofi will face margin pressure as pipeline depletion accelerates and vaccine business matures. This outcome was possible but seemed lower probability given evidence accumulating by June 2030 that AI discovery did improve productivity.

CEO leadership during this period represented successful navigation of business model disruption under conditions of uncertainty—responding to fundamental industry transformation while maintaining operational performance and shareholder value.

THE 2030 REPORT | Strategic Intelligence Division | June 2030 | Confidential | CEO Edition

REFERENCES & DATA SOURCES

1. Bloomberg (Q2 2030): "Sanofi Q2 2030 Earnings: Biotech Integration and AI Drug Development"
2. McKinsey & Company (2030): "AI-Driven Drug Discovery: Clinical Trial and Development Acceleration"
3. Reuters (2029): "Pharmaceutical Company Strategic M&A and Biotech Integration"
4. Morgan Stanley Healthcare Equity Research (June 2030): "Diversified Pharma Valuations"
5. Gartner (2029): "Healthcare AI and Precision Medicine Platforms"
6. Goldman Sachs (2030): "Pharmaceutical Sector Innovation and Competitive Positioning"
7. S&P Global (2030): "Pharmaceutical Industry Profitability and Technology ROI"
8. Deloitte (2030): "Pharmaceutical Digital Transformation"
9. Boston Consulting Group (2030): "Biopharma R&D Efficiency and Innovation"
10. Tufts Center for Drug Development (2030): "Pharmaceutical Development Productivity Trends"
11. Nature Medicine (2030): "AI Applications in Clinical Development"
12. EvaluatePharma (2030): "Drug Development Timeline and Success Rates"